Preliminary Study of Different Treatment Responses between Bevacizumab, Aflibercept and Dexamethasone Implant According to Renal Function in Diabetic Macular Edema Patients
Open Access
- 29 November 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 7047
Abstract
Background: The purpose of this study was to investigate the association between responses to intravitreal bevacizumab injection and renal function in diabetic macular edema (DME) patients. Methods: A retrospective study of the medical records of 104 treatment-naïve DME patients who received intravitreal bevacizumab injection (IVBI) was conducted. Based on the estimated glomerular filtration rate (eGFR, mL/min/1.73 m2), the participants were classified into three groups. Intergroup comparisons of the best-corrected visual acuity (BCVA) and central subfield retinal thickness (CST) changes were performed after three-monthly consecutive IVBIs. In the groups with decreased renal function, the response to further treatment with a different drug was investigated. Results: A total of 104 participants were included in the study: 60 participants in the preserved renal function group (eGFR ≥ 60), 25 participants in the moderate chronic kidney disease (CKD) group (30 ≤ eGFR < 60), and 19 participants in the severe CKD group (eGFR < 30). After three-monthly consecutive IVBIs, BCVA (p < 0.001) and CST (p < 0.001) were significantly improved only in the preserved renal function group. Following further treatment of patients with decreased renal function, the treatment results were significantly better in those who were switched to aflibercept or dexamethasone implant than in those who were maintained on IVBI. Conclusions: From this preliminary study, we observed that renal function might affect the response to IVBI treatment in patients with DME. In the case of a poor response to initial IVBI treatment for DME in patients with moderate to severe CKD, our study supports switching to the aflibercept or dexamethasone implant.Keywords
This publication has 30 references indexed in Scilit:
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular EdemaOphthalmology, 2014
- The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edemaJournal of Diabetes and its Complications, 2014
- Aqueous humour levels of placental growth factor in diabetic retinopathyActa Ophthalmologica, 2013
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edemaJournal of Diabetes and its Complications, 2011
- Placental Growth Factor in Patients with Decreased Renal FunctionRenal Failure, 2011
- Diabetic retinopathyThe Lancet, 2010
- Partial resolution of diabetic macular oedema after systemic treatment with furosemideBritish Journal of Ophthalmology, 2004
- Vascular Endothelial Growth Factor (VEGF)-Induced Retinal Vascular Permeability Is Mediated by Intercellular Adhesion Molecule-1 (ICAM-1)The American Journal of Pathology, 2000
- Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1Journal of Biological Chemistry, 1999